Background Most deaths in beta-thalassemia major result from cardiac complications due to iron overload. Differential effects on myocardial siderosis may exist between different chelators.
INTRODUCTION
Iron induced heart failure and arrhythmia are the commonest causes of death in beta thalassemia major, accounting for up to 71% of deaths in older series, 1, 2, 3 and 67% of deaths in a more recent report, despite improvements in overall survival. 4 There is a need therefore to identify myocardial siderosis early, and improve treatments for heart complications.
Myocardial siderosis can be identified by cardiovascular magnetic resonance (CMR) measurement of myocardial T2*, which is highly sensitive to tissue iron concentration, and this has been validated in the UK, 5, 6 and independently in the USA. 7 Patients having increased myocardial siderosis have been shown to be at increased risk of left ventricular (LV) systolic and diastolic dysfunction, 5, 7, 8, 9 arrhythmias, 7 and heart failure. 5, 10 In one series, patients presenting with heart failure had a mean T2* of 5.1 ms, 11 which is substantially below the normal lower limit of 20ms, 5 and another series showed 89% of patients presenting in heart failure having a T2* <10ms. 10 Myocardial T2* in normals is not affected by impaired left ventricular function, age, or infarction. 12 The T2* technique is fast, 13 and is highly reproducible between different MR scanners. 5, 14, 15, 16, 17 T2* calibration has been achieved for the liver in humans, 5, 18 in the heart in animals, 19 and will soon be available for the human heart. 20 Myocardial T2* can currently be used therefore to determine changes in human myocardial iron, but not the absolute myocardial iron concentration. The T2* technique shows improvement in myocardial siderosis in response to intravenous deferoxamine treatment in acute heart failure, 11 and a case controlled study found significantly less myocardial siderosis and improved LV ejection fraction (EF) in thalassemia patients treated with deferiprone compared with deferoxamine. 21 These data suggest that myocardial T2* has value for comparing the cardiac efficacy of chelators. We therefore compared these 2 treatments as monotherapy in a prospective, multi-center, randomized controlled trial, using Pennell et al the change over 1 year in myocardial T2* as the primary outcome measure, to determine whether deferiprone had superior cardiac efficacy compared with deferoxamine.
METHODS

Patient recruitment
This open-label trial was conducted in 4 centers in Italy and Greece. All patients had homozygous beta-thalassemia major, were regularly transfused and chelated with subcutaneous deferoxamine monotherapy, and had no symptoms of heart failure prior to screening. The mean dose of deferoxamine in the randomized patients prior to entry into the trial was 39 ±8 mg/kg/day for 5.7 days/week (equivalent to 32 mg/kg/day). Patients aged >18 years were screened (N=160) and selected if the myocardial T2* was abnormal (<20ms), but not severe (<8ms), and if the LV EF was >56%. No patient with symptomatic heart failure was eligible for the trial. This rationale excluded patients with no significant cardiac siderosis, and allowed patients with severe myocardial siderosis or LV dysfunction to receive best current clinical management. Sixty-one patients were randomized (figure 1). The reasons for screening failure (n=99) were usually a myocardial T2* outside the required range (<8ms in 11%; >20ms in 76%). Additional less common exclusions were LV EF <56% (2%); liver enzymes >3 times upper limit (3%); unsuitable psychological condition (1%); age <18 or >36 years (8%); claustrophobia (3%); pre-transfusion Hb <9g/dL (3%); refused or unable to participate (7%). Eighteen patients failed >1 criterion. Each center's ethics committee approved the study and patients gave signed informed consent. Secondary trial endpoints included cardiac volumes and function, liver iron concentration (LIC), and serum ferritin concentrations.
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Pennell et al Figure 1 . Screening, randomization, completion and withdrawal patient numbers.
Cardiovascular magnetic resonance
The T2* sequence was installed in Athens (GE CVi) and Cagliari (GE Signa Echo-speed).
Validation at each site included scanning of phantoms of known T2* value, the scanning of 5 patients at each site twice for local reproducibility, and rescanning within 3 days after flying to London for comparison with a reference scanner (Siemens Sonata). We predefined a limit of acceptability of 15% variation in T2* for each site compared with London. The variability compared with London was 9.7% in Athens, and 1.6% in Cagliari. Site interstudy variability was 3.5% and 2.4% respectively. These results, 15 and full details of the T2* MR sequence have been published. 13 Myocardial T2* was analysed using dedicated software (Thalassemia-Tools; Cardiovascular Imaging Solutions, London, UK) with consistent regions of interest in the ventricular septum which avoid susceptibility artefacts, 5, 22 as previously described. 13, 14 Cardiac volumes were acquired using contiguous steady state free precession short axis cines All measurements were made in London by 2 reviewers in consensus who were blinded to treatment allocation. Trial analyses were not fed back to the centers during the trial
Other iron measurements
LIC was assessed at baseline and 12 months using a superconducting quantum interference device (SQUID). 25 All the measurements were centralized at the Turin University facility (Model 5700 3-Channel SQUID, Tristan Technologies). 26 Prior to the start of the trial, SQUID was considered the best non-invasive technique for measuring liver iron. Serum ferritin was measured at baseline and 3 monthly. Serum was separated, labeled and stored frozen at -20ºC until shipped to a central laboratory, where it was measured by microparticle enzyme immunoassay (Abbott AXSYM System).
Safety assessments
Patients were monitored weekly for absolute neutrophil count (ANC) and any adverse events.
Serum alanine transaminase (ALT) levels were measured quarterly, serum zinc levels were measured at baseline, and 6 monthly, and serum creatinine levels were measured at baseline and 12 months.
Statistical analysis
The statistical analysis plan was defined prior to breaking the randomization code and locking of the database of the study. All continuous parameters were analyzed using the 2-sample ttest, using a p-value of 0.05 as the threshold for statistical significance. Since tissue iron is Pennell 
RESULTS
Patient characterization
The baseline characteristics are shown in table 1. The groups were well matched for the primary endpoint of myocardial siderosis. Matching was good for most other measures Pennell et al including liver iron and transfusional iron input, but significant differences were present for the serum ferritin, hemoglobin and white cell count. 
Vital signs
Weight gain was greater with deferiprone at 6 months (1.6 ±1.8 vs -0.22 ±2.7kg; p=0.0035), and at 12 months (2.2 ±3.0 vs 0.1 ±2.7kg; p=0.0043). There were no significant differences between groups in other vital signs.
Other laboratory measures
The difference between the deferiprone and deferoxamine groups in change of ALT level at 12 months was not significant (22.9 ±48.6 vs 4.7 ±38.2 U/L; p=0.11). This includes the 2 patients who dropped out for increased serum enzyme levels. There was no significant difference in trend of ALT over time between groups (p=0.32). The difference in percentage of patients with ALT greater than twice the upper limit was not significant at baseline or at 12
months.
There was no significant difference between groups in the change of zinc level at 12 months (-0.80 ±2.8 vs 0.23 ±2.3umol/L; p=0.12). There was no significant difference between groups in the change in creatinine at 12 months (3.24 ±10.5 vs 0.06 ±12.7umol/L; p=0.29). There were no significant differences between groups in other laboratory data including ANC.
Adverse events
The most frequent adverse events with deferiprone were gastrointestinal symptoms (nausea, vomiting, or abdominal pain), which occurred in 19 (66%) patients. These usually occurred in the first weeks of treatment, were mild to moderate, and usually resolved within a median of 3 days (range 1-17 days) without discontinuation or decreasing the dose of deferiprone.
Deferoxamine adverse events included reactions at the infusion site, which occurred in 12 
DISCUSSION
Heart disease, which results from myocardial iron deposition associated with life-long blood transfusions and increased gut iron uptake, is the commonest cause of death in betathalassemia major. Recently it has become possible to target therapy for myocardial siderosis using myocardial T2* allowing comparison of the myocardial efficacy of iron chelators.
Using myocardial T2*, continuous intravenous deferoxamine has been shown to reduce myocardial siderosis in acute heart failure, 11 although iron clearance was considerably slower from heart than liver. In the current trial, all screened patients had no cardiac symptoms and were receiving chronic deferoxamine monotherapy, and those who were subsequently randomized either continued deferoxamine at an increased dose (+4 mg/kg/day, p= 0.001) following entry into the trial with standardization of treatment, or were switched to deferiprone monotherapy. We found a significant reduction in our primary trial endpoint of myocardial siderosis in the deferoxamine group (T2* increased by 13% at 12 months, p<0.001) which probably resulted from the increased dose of deferoxamine, and/or improved compliance. Despite this improvement in the control group, the deferiprone group showed superior efficacy in reducing myocardial siderosis (T2* increased by 27% at 12 months, p<0.001; p=0.023 vs deferoxamine group at 12 months). These data accord with a previous 21 Although the clinical efficacy of raising myocardial T2* for asymptomatic patients remains to be determined, it would appear that reduced levels of myocardial iron are a favorable response.
The deferiprone group also exhibited significantly improvement in secondary trial endpoints compared with deferoxamine, with a reduced end-systolic volume and increased EF. In this trial, we excluded patients with an EF <56% by CMR, which is the lower limit for nonanemic subjects. 28 We believed this was sufficient evidence that significant LV systolic dysfunction was present and that best current medical treatment should be offered outside the trial setting. However, "normal" cardiac volumes and function in thalassemia are not well defined. Compared with normal non-anemic subjects, thalassemia patients' hearts have larger end-diastolic volumes and increased cardiac output, 7, 29, 30 which allows for increased perfusion for tissue oxygenation requirements. In addition, the ejection fraction in thalassemia major patients with no iron loading (T2* >20ms), is higher than in controls with a lower limit of up to 63%. 5, 7, 30 Thus, because the EF in thalassemia without myocardial siderosis is higher than in normals, we believe that our trial included patients with sub-clinical LV dysfunction. The increase in EF seen in this trial accords with this view, and suggests that deferiprone was effective in relieving this dysfunction. Reduced EF is linked with adverse survival not only in thalassemia, 31 but also in coronary artery disease, 32 and heart failure, 33 and improved prognosis occurs with treatments that improve EF. 34, 35 Deferiprone also reduced end-systolic volume, another prognostic parameter in large, 36 and normal sized hearts. 37 Heart failure treatments known to improve prognosis reduce the end-systolic volume, 38 although this has not been shown directly in thalassemia patients. These prospective randomized data are also consistent with a previous study showing significantly superior EF with deferiprone. 21 Pennell et al It therefore appears that deferiprone could reduce the risk of progression to iron-related cardiomyopathy by removing more cardiac iron than subcutaneous deferoxamine, and the LV function and volume improvements in patients with sub-clinical LV dysfunction could yield prognostic benefit. Lower levels of myocardial siderosis would allow an increased reserve for any future periods of iron loading, and the potential for greater resistance to catastrophic heart failure that can be seen in thalassemia patients with intercurrent infection. These interpretations accord with longitudinal studies of EF in thalassemia, 31 and previous retrospective survival data using deferiprone or deferoxamine. 39 With >4 years of follow-up, cardiac dysfunction was newly diagnosed in 4% of the deferiprone-treated patients and 20% of the deferoxamine-treated patients (p=0.007). This was accompanied by no deaths with deferiprone but 3 cardiac-related deaths with deferoxamine.
These findings suggest differences in the in-vivo myocardial efficacy of these drugs.
Deferoxamine is an important chelator, 40, 41, 42 but is a large positively charged molecule, relatively lipophobic, and one which undergoes conformation change on binding of iron which may lead to intracellular trapping. 43 These properties potentially limit its ability to chelate intracellular iron, unless there is an active excretion pathway, as postulated for deferoxamine in hepatocytes. 43, 44 By contrast, deferiprone is a small, neutral molecule with greater lipophilicity, and therefore has significantly greater potential to chelate intracellular iron. 45, 46 This suggests that deferiprone may have preferential access to intracellular iron in tissues such as the myocardium, and in-vitro and animal data support this hypothesis. 47 Because of these variations in action, combination therapy with these chelators may be attractive for which there is supportive in-vitro, 47 and clinical evidence. 48 Combination therapy is being subjected to a further randomized controlled trial for cardiac efficacy. 49 Heart chelation RCT No difference was found between groups in serum ferritin or T2 weighted myocardial signal intensity ratio (SIR). Peng compared deferiprone (75mg/kg/day) with deferoxamine (50mg/kg/day for ≥5 days/week). 51 Deferiprone resulted in a significantly larger improvement in SIR and EF. Galia compared deferiprone (75mg/kg/day) with deferoxamine (50mg/kg/day for 6 days/week). 52 No significant differences between groups were demonstrated in myocardial SIR or EF. Our current trial differs from these reports in several ways which might explain the efficacy of deferiprone which we found: first, the current trial used deferiprone at 100mg/kg/day; second, compliance was high in the current study, but was not quantified in the previous reports and may have been lower; third, the prior studies used heart SIR to measure myocardial siderosis, which is not an absolute measure and is sensitive to noise, limiting both its reproducibility and interpretation; fourth, the current trial is multicenter and not single center. Our results are consistent with another randomized controlled trial from Olivieri, which has only been published in abstract form; deferiprone (75mg/kg/day) resulted in a significant increase in T2 relaxation time, which was not matched by deferoxamine (50mg/kg/day). 53 The patients in the current study were well-matched at baseline for the primary endpoint of myocardial T2*, and they were also well-matched for the secondary endpoint of liver iron.
However, the accuracy of SQUID may vary between machines and direct comparison of absolute liver iron levels with studies relating our single center SQUID results to those from other centers may not be straightforward. Despite these issues, it is worth noting that at baseline our patients had a median LIC of 4.30mg/g dw, with only 8% having an LIC >15mg/g dw. Therefore the patients in the current study would appear to be reasonably well-Heart chelation RCT Page 20 Pennell et al chelated by liver criteria. In the current study, the 1.5 mg/g dw reduction in LIC over 12 months with deferoxamine was significant, whereas the 0.94 mg/g dw reduction with deferiprone did not achieve significance, although the between groups comparison was not significant. This is the first randomized controlled study to compare changes in LIC at the highest dose of deferiprone currently approved in Europe (100mg/kg/day). Deferiprone appeared to prevent liver iron accumulation, even if the mean decrease appeared marginally less effective than deferoxamine. The patients in our study showed a difference at baseline for the secondary endpoint of serum ferritin. The explanation for this difference is the presence of 2 extreme outliers in the deferoxamine group with very high ferritin levels. After log transformation to achieve a normal distribution, no difference between groups at baseline was present. This lack of difference accords with the lack of baseline statistical difference in the direct measures of liver or myocardial iron. After controlling for the baseline serum ferritin status (>2500 ug/L or <=2500 ug/L) in a covariate analysis, the difference in myocardial T2* at month 12 between the treatment groups remained significant (p=0.032), favoring the deferiprone treatment group, and there was no difference in trend of serum ferritin over time between treatment groups.
Compliance with deferiprone at 100mg/kg/day was excellent with no new drug-related complications compared with previous lower dose trials. Contrary to other trials where deferiprone was interrupted at the first sign of neutropenia (<1.5x10 9 /L), we allowed continuation of deferiprone if the neutrophil count remained above 1.0x10 9 /L. One patient experienced one episode of neutropenia, which resolved without discontinuing deferiprone.
No agranulocytosis was seen. Two deferiprone treated patients discontinued the study due to increased liver enzymes, which returned to baseline levels upon interruption of therapy. One deferoxamine-patient developed arrhythmias and a reduction in EF, though still in the normal Pennell et al range, and an increase in the LV and atrial diameters and was withdrawn from the study for initiation of intensive chelation therapy. Two other deferoxamine-patients discontinued the study for personal reasons.
Limitations
The results of this trial are relevant to patients with no symptoms of heart failure, and who are older than 18 years. Evidence that these findings apply to symptomatic patients, or children awaits trials in these specific populations.
Conclusions
At the doses used in this prospective trial, deferiprone was superior to deferoxamine over 1
year in improving myocardial siderosis in asymptomatic patients with beta-thalassemia major, and this confirms previous retrospective data. This suggests that deferiprone has superior access to myocardial iron stores compared with deferoxamine, which accords with in-vitro data. The combination of detection of myocardial siderosis by T2* CMR and the superior effect of deferiprone in removal of cardiac iron allows a rational paradigm of early management of cardiac siderosis in patients maintained on long term deferoxamine, and this should translate into improved survival.
